International Alliance for Personalised Medicine (IPM Alliance) shared a post on LinkedIn:
“Launching the IPM Brief: Where Personalised Medicine Meets Policy, Access, and Implementation
Keeping up with healthcare policy, personalised medicine, regulation, reimbursement, diagnostics, and innovation can feel like a full-time job.
Every week brings new legislation, funding decisions, technology breakthroughs, regulatory developments, and access challenges that can shape the future of healthcare.
That’s exactly why we launched the IPM Brief.
Twice a week, we cut through the noise and deliver the developments, decisions, and debates that matter most, curated for policymakers, healthcare leaders, patient advocates, payers, researchers, industry partners, and everyone working to advance personalised medicine.
No endless scrolling. No information overload. Just clear, concise intelligence on the policies, innovations, and system changes influencing healthcare across Europe and beyond.
Read it in five minutes.
Stay informed all week.
Focus on what matters.
Yesterday we launched the first issue of the IPM Brief, where we focused on:
- How Chinese biotech is increasingly influencing the global oncology landscape and challenging established innovation models
- Why eligibility for a therapy does not necessarily translate into access for patients
- How reimbursement, pricing, and regulatory decisions are becoming as important as scientific breakthroughs in determining outcomes
- Key developments from American Society of Clinical Oncology (ASCO) and what they could mean for the future of cancer care
Read the full brief here.
Sign up here to recieve our brief.”
Other articles from IPM Alliance on OncoDaily.